Faeth Therapeutics, Inc.

FTH

$39.00

-0.31%

N/A-$0.12

Healthcare

Biotechnology

NASDAQ

Active Trading

Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. ...

Fundamental Analysis of FTH

Key Strengths

Mechanistic differentiation: multi-node inhibition of the PI3K/AKT/mTOR (PAM) pathway, a validated and highly prevalent oncogenic signaling axis

All-oral regimen approach (PIKTOR/PIK-201 platform), which can improve adherence and potentially broaden combination strategies

Risk Factors

Clinical binary risk: outcomes in Phase 2/near-Phase 3 settings can materially change valuation, with potential for readouts to disappoint or be inconclusive

Sustained losses: negative net income and negative operating cash flow indicate continued capital needs and high dependence on financing conditions

Profitability

Net Margin4030.69%

Operating Margin4098.54%

Valuation

P/E Ratio-0.28x

Current Ratio19.69

Efficiency

ROE-192.76%

ROA-103.29%

Fundamental Analysis of FTH

Faeth Therapeutics is a clinical-stage biotech focused on “multi-node” inhibition of the PI3K/AKT/mTOR (PAM) pathway using an all-oral combination approach. The core investment thesis is therefore driven less by current financial performance and more by the probability-weighted outcome of late-stage clinical catalysts (notably PIKTOR/PIK-201 in endometrial cancer, plus additional indications later). In this context, fundamentals are defined by (1) financial runway, (2) clinical progress credibility, and (3) balance-sheet risk from dilution. On liquidity, the company screens well: FY2025 operating cash flow was about -$20.5M, yet the reported current ratio is very high (5.06 in the provided highlights; other dataset snapshot shows an even larger TTM current ratio). This suggests management has maintained adequate near-term resources to fund trials through upcoming readouts. However, profitability remains deeply negative: FY2025 net income was -$21.1M with diluted EPS of -16.72, and operating cash flow and operating income are negative. Margins and valuation multiples such as P/E are not meaningful in a standard way due to losses (P/E is shown as negative in the provided dataset). Return metrics (ROE/ROA) are also strongly negative given operating losses. Catalysts appear near-term and can be binary in biotech: the next scheduled readout is PIK-201 topline data expected around early September 2026, with additional PIKTOR topline expected by year-end 2026. News flow has been supportive (e.g., FDA Fast Track designation). The insider/ownership signals are also mixed-to-positive, with recent insider buying reported and relatively low short interest (about 3.3% of float; ~2.8 days to cover), which can reduce downside pressure from forced covering, though it does not remove fundamental execution risk. Overall, for long-term investors, FTH’s “fundamental” profile is best viewed as a clinical development bet with a liquidity buffer, where the key determinant of value creation will be whether PAM multi-node therapy demonstrates clinically meaningful and durable efficacy with an acceptable safety/tolerability profile. Until there is clear evidence of trial success and sustainable progress toward regulatory endpoints, the risk remains elevated and the stock is likely to remain volatile around clinical timing.

Key Strengths of FTH

Mechanistic differentiation: multi-node inhibition of the PI3K/AKT/mTOR (PAM) pathway, a validated and highly prevalent oncogenic signaling axis
All-oral regimen approach (PIKTOR/PIK-201 platform), which can improve adherence and potentially broaden combination strategies
Regulatory momentum: FDA Fast Track designation reported for PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer
Near-term liquidity support: strong reported current ratio and sizable working-capital position for a small-cap biotech
Clinical-operations focus with multiple upcoming catalysts (PIK-201 topline and PIKTOR topline expected in 2026)
Relatively low short interest as a share of float, which may reduce near-term bearish positioning pressure

Risk Factors of FTH

Clinical binary risk: outcomes in Phase 2/near-Phase 3 settings can materially change valuation, with potential for readouts to disappoint or be inconclusive
Sustained losses: negative net income and negative operating cash flow indicate continued capital needs and high dependence on financing conditions
Dilution risk: biotechnology development often requires equity/debt financing; upcoming events and option activity can increase dilution over time
Valuation uncertainty: with losses, conventional valuation metrics (P/E, earnings yield) are not informative and market pricing can be sentiment-driven
Safety/tolerability risk for pathway inhibitors: PAM pathway modulation can lead to clinically meaningful toxicities that may limit therapeutic window
Concentration risk in oncology programs: limited diversification across indications/stages until multiple programs show success

Market Cap vs Revenue & Earnings

Earnings

n/a

Revenue

n/a

Market cap

$1.00B

-0.3x

P/E Ratio

-207.1x

P/S Ratio

Earnings & Revenue

Last Reportedn/a

Earnings per share (EPS)n/a

Gross Margin2740.82%

Net Profit Margin4030.69%

Debt/Equity Ratio0.00

Profitability Bridge (Current vs YoY)

How gross, operating and net margins shifted versus last year.

Revenue / Net Income / FCF History (USD B)

Growth Signals of FTH

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Revenue	—	—	—	—	Flat
Diluted EPS	—	—	—	—	Flat
Free Cash Flow	—	—	—	—	Flat

Profitability of FTH

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Net Margin	—	0.00%	—	—	Flat
Operating Margin	—	0.00%	—	—	Flat
ROE	—	—	—	—	Flat

Financial Health of FTH

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
Current Ratio	—	19.693	—	—	Flat
Quick Ratio	—	19.693	—	—	Flat
Debt / Equity	—	0.003	—	—	Flat

Valuation of FTH

Metric	Current	Previous	YoYYear-over-Year change: current quarter versus the same quarter last year.	QoQQuarter-over-Quarter change: current quarter versus the immediately previous quarter.	Signal
P/E	—	-2.20x	—	—	Flat
P/B	—	0.82x	—	—	Flat

Supply Chain of FTH

RELATIONS

Upstream

BYD Company LimitedHKEx:1211Mercedes-Benz Group AGXETRA:MBGMAN Truck & Bus SE (a TRATON SE brand)XETRA:8TRAScania AB (a TRATON SE brand)XETRA:8TRAVolvo Group (AB Volvo)STO:VOLV-BMarcopolo S.A.BOVESPA:POMO4Sasol LimitedJSE:SOLEngen Petroleum (Vivo Energy / Vitol)Bridgestone CorporationTSE:5108The Goodyear Tire & Rubber CompanyNASDAQ:GTContinental AGXETRA:CONTRATON SEXETRA:8TRAVolkswagen AGXETRA:VOWContemporary Amperex Technology Co., Limited (CATL)SHE:300750Multimech (Pty) Ltd

Downstream

Commuting Public (Cape Town Metro)Western Cape Government (Dept. of Transport & Public Works)School Transport Contracts (Various Schools in Western Cape)Tour Operators and Corporate Travel ClientsAlpine Truck and Bus (Pty) Ltd (51% owned subsidiary)Frontier Tyres (wholly owned subsidiary)Sibanye Bus ServicesTable Bay Area Rapid Transit (TBRT) / MyCiTiN2 Express (Pty) Ltd

Proxies

Hosken Consolidated Investments LimitedJSE:HCIZeda Limited (formerly Car Rental / Transport peer)JSE:ZEDFirstGroup plcLSE:FGPNational Express Group PLCLSE:NEX

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer